<code id='B8990F52BB'></code><style id='B8990F52BB'></style>
    • <acronym id='B8990F52BB'></acronym>
      <center id='B8990F52BB'><center id='B8990F52BB'><tfoot id='B8990F52BB'></tfoot></center><abbr id='B8990F52BB'><dir id='B8990F52BB'><tfoot id='B8990F52BB'></tfoot><noframes id='B8990F52BB'>

    • <optgroup id='B8990F52BB'><strike id='B8990F52BB'><sup id='B8990F52BB'></sup></strike><code id='B8990F52BB'></code></optgroup>
        1. <b id='B8990F52BB'><label id='B8990F52BB'><select id='B8990F52BB'><dt id='B8990F52BB'><span id='B8990F52BB'></span></dt></select></label></b><u id='B8990F52BB'></u>
          <i id='B8990F52BB'><strike id='B8990F52BB'><tt id='B8990F52BB'><pre id='B8990F52BB'></pre></tt></strike></i>

          entertainment

          entertainment

          author:Wikipedia    Page View:2

          Does biotech prepare you for the presidency? Who really wants to gut the FDA? And why do drug companies struggle with IT?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss how Vivek Ramaswamy, fresh off his headline-grabbing debut at the first Republican presidential debate, went from a drug industry entrepreneur to a GOP rising star — and how his former biotech colleagues are reacting to it. We also explain the latest news in the life sciences, including a curious data leak and the family business of a famed biotech inventor.

          advertisement

          For more on what we cover, here’s more on Ramaswamy; here’s the news on the data leak; here’s the story on the latest Langer venture; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          focus

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Carvykti CAR
          Carvykti CAR

          Acutemyeloidleukemiacellsamidbloodflow.AdobeTheFoodandDrugAdministrationissuedachangetothewarninglab

          read more
          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more

          Three trends to watch in biotech in 2024

          ChristineKao/STATEverywinter,likePunxsutawneynobles,biotech’smanythoughtleadersgatherfortheJ.P.Morga